Iceland· IS-EU/1/21/1593/006 -010
Cibinqo
A abrocitinib product containing abrocitinibum inn, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Abrocitinib is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH08 (abrocitinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Abrocitinib · ATC D11AH08
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abrocitinib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.26 in France to $295.64 in United States — a ×1143 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Abrocitinib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- US United States$295.64 (acquisition cost)
- CH Switzerland$122.11
- FR France$0.26
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Abrocitinibum INN
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- D11AH08
- ATC class
- Abrocitinib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean52260628 stk x1 þpakkiISK 173710
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Abrocitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCibinqoPfizer Laboratories Div Pfizer Inc
- CzechiaCIBINQOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandCibinqo
- FranceCIBINQO 100 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumCibinqo 100 mgPfizer Europe MA
- NetherlandsCibinqo 100 mg, filmomhulde tablettenPfizer Europe MA EEIG
- NorwayCibinqoPfizer Europe MA EEIG
- PolandCibinqoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Cibinqo
- Norway · Cibinqo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3d80c1a5-c5d6-44e6-b452-726cee50d578 GET /v1/drugs/3d80c1a5-c5d6-44e6-b452-726cee50d578?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "D11AH08",
"marketed": true,
"strength": "100 mg",
"ma_number": "EU/1/21/1593/006 -010",
"substance": "Abrocitinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í ofnæmis- og lungnasjúkdómum og sérfræðinga í húðsjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44539"
}See everything about abrocitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.